15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

Gil Yosipovitch; Thomas Bieber; Linda Stein Gold; Shawn Kwatra; Svitlana Tatulych; Chudy Nduaka; Michael C. Cameron; David Williams; Pinaki Biswas; Hernan Valdez

doi:10.1016/j.jaad.2020.06.252

Journal article

15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial

Gil Yosipovitch, Thomas Bieber, Linda Stein Gold, Shawn Kwatra, Svitlana Tatulych, Chudy Nduaka, Michael C. Cameron, David Williams, Pinaki Biswas and Hernan Valdez

Journal of the American Academy of Dermatology, Vol.83(6), pp.AB41-AB41

2020-12-01

DOI: https://doi.org/10.1016/j.jaad.2020.06.252

Metrics

2 Record Views

Details

Title: 15517 Eczema Area and Severity Index 90 (EASI-90) responder rates with abrocitinib and relationship with quality of life (QoL) and itch in patients with moderate to severe atopic dermatitis: Results from a randomized phase 3 clinical trial
Creators: Gil Yosipovitch
Thomas Bieber
Linda Stein Gold
Shawn Kwatra
Svitlana Tatulych
Chudy Nduaka
Michael C. Cameron
David Williams
Pinaki Biswas
Hernan Valdez
Publication Details: Journal of the American Academy of Dermatology, Vol.83(6), pp.AB41-AB41
Academic Unit: Miller School of Medicine; UMMG Dept of Dermatology & Cutaneous Surgery
Language: English
Resource Type: Journal article
Record Identifier: 991031713249202976